Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) rose 7.8% on Friday . The company traded as high as $8.31 and last traded at $8.19. Approximately 446,675 shares traded hands during trading, a decline of 63% from the average daily volume of 1,209,699 shares. The stock had previously closed at $7.60.
Analysts Set New Price Targets
Several analysts recently weighed in on the company. D. Boral Capital reissued a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a report on Monday, November 25th. HC Wainwright reiterated a "buy" rating and set a $40.00 price objective on shares of Anavex Life Sciences in a research report on Wednesday, November 27th.
Read Our Latest Stock Report on Anavex Life Sciences
Anavex Life Sciences Stock Performance
The stock has a market cap of $690.27 million, a P/E ratio of -16.28 and a beta of 0.73. The stock's fifty day simple moving average is $7.05 and its 200-day simple moving average is $5.86.
Institutional Trading of Anavex Life Sciences
A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in Anavex Life Sciences during the second quarter worth about $57,000. Orion Capital Management LLC boosted its position in shares of Anavex Life Sciences by 666.7% in the 3rd quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 10,000 shares in the last quarter. PVG Asset Management Corp purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter worth approximately $74,000. Atria Investments Inc bought a new position in Anavex Life Sciences during the 3rd quarter valued at approximately $76,000. Finally, BNP Paribas Financial Markets raised its stake in Anavex Life Sciences by 97.0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company's stock valued at $86,000 after buying an additional 7,421 shares during the last quarter. 31.55% of the stock is owned by hedge funds and other institutional investors.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Further Reading
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
